REHOVOT, Israel, April 30, 2019 /PRNewswire/ -- Evogene Ltd.
(NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company
developing novel products for life science markets, announced today
that it has filed its annual report on Form 20-F for the fiscal
year ended December 31,
2018 with the U.S. Securities and Exchange
Commission (the "SEC").
The annual report, which contains the Company's audited
consolidated financial statements, can be accessed on the SEC
website at http://www.sec.gov/ as well as via the Company's
website at http://www.evogene.com/investor-relations. The Company
will deliver a hard copy of its annual report, including its
complete audited consolidated financial statements, free of charge,
to its shareholders upon request to the Company Media
Contact: ir@evogene.com.
About Evogene Ltd.:
Evogene (NASDAQ: EVGN) (TASE: EVGN) is a leading biotechnology
company developing novel products for major life science markets
through the use of a unique computational predictive biology (CPB)
platform incorporating deep scientific understandings and advanced
computational technologies. Today, this platform is utilized by the
Company to discover and develop innovative products in the
following areas (via subsidiaries or divisions): ag-chemicals,
ag-biologicals, seed traits, integrated castor oil ag-solutions and
human microbiome based therapeutics. Each subsidiary or division
establishes its product pipeline and go-to-market, as demonstrated
in its collaborations with world-leading companies such as BASF,
Corteva, Bayer and ICL. For more information, please visit
www.evogene.com
Forward Looking Statements:
This press release contains "forward-looking statements"
relating to future events. These statements may be identified by
words such as "may", "could", "expects", "intends", "anticipates",
"plans", "believes", "scheduled", "estimates" or words of similar
meaning. Such statements are based on current expectations,
estimates, projections and assumptions, describe opinions about
future events, involve certain risks and uncertainties which are
difficult to predict and are not guarantees of future performance.
Therefore, actual future results, performance or achievements of
Evogene may differ materially from what is expressed or implied by
such forward-looking statements due to a variety of factors, many
of which beyond Evogene's control, including, without limitation,
those risk factors contained in Evogene's reports filed with the
appropriate securities authority. Evogene disclaims any obligation
or commitment to update these forward-looking statements to reflect
future events or developments or changes in expectations,
estimates, projections and assumptions.
Contact:
Nir Zalik
IR/PR Manager
E: IR@evogene.com
T: (+972)-8-931-1963
US Investor Relations
Vivian Cervantes
PCG Advisory
E: vivian@pcgadvisory.com
T: 646-863-6274
T: (+972)-8-931-1963
US Investor Relations
Vivian Cervantes
PCG Advisory
E: vivian@pcgadvisory.com
T: 646-863-6274
View original
content:http://www.prnewswire.com/news-releases/evogene-files-annual-report-for-the-year-ended-december-31-2018-300840521.html
SOURCE Evogene